Cancer Research Grants Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4023-4029, August 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hisatake, J.-i.
Right arrow Articles by Koeffler, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hisatake, J.-i.
Right arrow Articles by Koeffler, H. P.
[Cancer Research 59, 4023-4029, August 15, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

5,6-trans-16-ene-Vitamin D3: A New Class of Potent Inhibitors of Proliferation of Prostate, Breast, and Myeloid Leukemic Cells1

Jun-ichi Hisatake2, Tetsuya Kubota, Yasuko Hisatake, Milan Uskokovic, Shigeru Tomoyasu and H. Phillip Koeffler

Division of Hematology/Oncology, Cedars-Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048 [J-i. H., T. K., Y. H., H. P. K.]; Hoffmann LaRoche, Inc., Nutley, New Jersey 07110 [M. U.]; and Department of Hematology, Showa University School of Medicine, Tokyo, Japan [S. T.]

The 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the physiologically active form of vitamin D3 that inhibits proliferation and induces differentiation of a variety of malignant cells. We evaluated a newly synthesized vitamin D3 analogue [1,25(OH)2-16-ene-5,6-trans-D3 (Ro 25-4020)] that has a novel 5,6-trans motif. Dose-response studies showed that 1,25(OH)2-16-ene-5,6-trans-D3 had 10–100-fold greater antiproliferative activities than 1,25(OH)2D3 when measuring clonal growth of breast (MCF-7) and prostate (LNCaP) cancer cell lines as well as a myeloid leukemia cell line (HL-60). Because the chief toxicity of vitamin D3 is hypercalcemia, we examined the calcemic activity of 1,25(OH)2-16-ene-5,6-trans-D3 in mice. Remarkably, 1,25(OH)2-16-ene-5,6-trans-D3 was at least 40-fold less calcemic as compared with 1,25(OH)2D3 and 1,25(OH)2-16-ene-D3 (Ro 24-2637). To explore the mechanism by which the 1,25(OH)2-16-ene-5,6-trans-D3 analogue mediated its antiproliferative activity, several studies were performed. Pulse-exposure studies showed that a 4-day pulse exposure to 1,25(OH)2-16-ene-5,6-trans-D3 (10-7 M) in liquid culture was adequate to achieve a 40% inhibition of MCF-7 clonal growth in the absence of the analogue, suggesting that the growth inhibition mediated by 1,25(OH)2-16-ene-5,6-trans-D3 was at least in part irreversible. Cell cycle studies showed that 1,25(OH)2-16-ene-5,6-trans-D3 increased the proportion of MCF-7 cells in the G0-G1 phase and decreased those in the S phase. Furthermore, 1,25(OH)2-16-ene-5,6-trans-D3 induced an elevated expression of the cyclin-dependent kinase inhibitors, p21waf1 and p27kip1. In addition, 1,25(OH)2-16-ene-5,6-trans-D3 almost completely inhibited telomerase activity, as measured by telomeric repeat amplification protocol assay and human telomerase reverse transcriptase mRNA. For each of the growth-related parameters that were examined, the vitamin D3 analogue was more active than 1,25(OH)2D3. In contrast, 1,25(OH)2D3 was more calcemic than 1,25(OH)2-16-ene-5,6-trans-D3. In summary, 1,25(OH)2-16-ene-5,6-trans-D3, having a novel 5,6-trans motif, strongly inhibited clonal proliferation and reduced telomerase activity with low calcemic activity, suggesting further testing in in vivo cancer models. This analogue may gain a therapeutic niche for selected malignancies.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
Z. G. Dikmen, G. C. Gellert, S. Jackson, S. Gryaznov, R. Tressler, P. Dogan, W. E. Wright, and J. W. Shay
In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Cancer Res., September 1, 2005; 65(17): 7866 - 7873.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kumagai, L.-Y. Shih, S. V. Hughes, J. C. Desmond, J. O'Kelly, M. Hewison, and H. P. Koeffler
19-Nor-1,25(OH)2D2 (a Novel, Noncalcemic Vitamin D Analogue), Combined with Arsenic Trioxide, Has Potent Antitumor Activity against Myeloid Leukemia
Cancer Res., March 15, 2005; 65(6): 2488 - 2497.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. V. Stewart and N. L. Weigel
Vitamin D and Prostate Cancer
Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Asai, Y. Oshima, Y. Yamamoto, T.-a. Uochi, H. Kusaka, S. Akinaga, Y. Yamashita, K. Pongracz, R. Pruzan, E. Wunder, et al.
A Novel Telomerase Template Antagonist (GRN163) as a Potential Anticancer Agent
Cancer Res., July 15, 2003; 63(14): 3931 - 3939.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. A. Wetterau, M. J. Francis, L. Ma, and P. Cohen
Insulin-Like Growth Factor I Stimulates Telomerase Activity in Prostate Cancer Cells
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3354 - 3359.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. M. Peehl, A. V. Krishnan, and D. Feldman
Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer
J. Nutr., July 1, 2003; 133(7): 2461S - 2469.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Kumagai, J. O'Kelly, J. W. Said, and H. P. Koeffler
Vitamin D2 Analog 19-nor-1,25-Dihydroxyvitamin D2: Antitumor Activity Against Leukemia, Myeloma, and Colon Cancer Cells
J Natl Cancer Inst, June 18, 2003; 95(12): 896 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
Y.-S. Cong, W. E. Wright, and J. W. Shay
Human Telomerase and Its Regulation
Microbiol. Mol. Biol. Rev., September 1, 2002; 66(3): 407 - 425.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J.-i. Hisatake, J. O'Kelly, M. R. Uskokovic, S. Tomoyasu, and H. P. Koeffler
Novel vitamin D3 analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D3, that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells
Blood, April 15, 2001; 97(8): 2427 - 2433.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Mehta, M. Hawthorne, L. Uselding, D. Albinescu, R. Moriarty, K. Christov, and R. Mehta
Prevention of N-Methyl-N-Nitrosourea-Induced Mammary Carcinogenesis in Rats by 1{alpha}-Hydroxyvitamin D5
J Natl Cancer Inst, November 15, 2000; 92(22): 1836 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. W. Kensler, P. M. Dolan, S. J. Gange, J.-K. Lee, Q. Wang, and G. H. Posner
Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis
Carcinogenesis, July 1, 2000; 21(7): 1341 - 1345.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. C. Chen, G. G. Schwartz, K. L. Burnstein, B. L. Lokeshwar, and M. F. Holick
The in Vitro Evaluation of 25-Hydroxyvitamin D3 and 19-nor-1{{alpha}},25-Dihydroxyvitamin D2 as Therapeutic Agents for Prostate Cancer
Clin. Cancer Res., March 1, 2000; 6(3): 901 - 908.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. Feldman, X.-Y. Zhao, and A. V. Krishnan
Editorial/Mini-Review: Vitamin D and Prostate Cancer
Endocrinology, January 1, 2000; 141(1): 5 - 9.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. M. Lippman and P. H. Brown
Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost
J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Ogretmen, D. Schady, J. Usta, R. Wood, J. M. Kraveka, C. Luberto, H. Birbes, Y. A. Hannun, and L. M. Obeid
Role of Ceramide in Mediating the Inhibition of Telomerase Activity in A549 Human Lung Adenocarcinoma Cells
J. Biol. Chem., June 29, 2001; 276(27): 24901 - 24910.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.